Health systems’ rare rejection of Alzheimer’s drug sparks questions about FDA approvals
July 24, 2021
While heightened controversy and discussion is rare for Food and Drug Administration-approved drugs, outcry over the Alzheimer’s drug Aduhelm could lead to a broader conversation about the approval process and what patients and providers are looking for with value-based care.
Read the source article at Home | Modern Healthcare
2021-07-20 22:17:17